Form 4: Verve Therapeutics CEO Transfers 30,000 Shares to Family Trust

Verve Therapeutics CEO, Sekar Kathiresan, transferred 30,000 shares of company stock to a family trust on December 4, 2024.

Summary

• On December 4, 2024, Sekar Kathiresan, CEO of Verve Therapeutics, transferred 30,000 shares of Verve common stock to a family trust.
• The beneficiaries of this trust are members of Mr. Kathiresan's immediate family.
• Following the transaction, Mr. Kathiresan directly owns 323,508 shares and indirectly owns 110,997 shares through the Sekar Kathiresan 2021 Irrevocable Trust and 240,997 shares through the Kathiresan Family 2021 Irrevocable Trust.
• The direct holdings include 2,380 shares acquired through the company's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not contain any information that would indicate a positive or negative sentiment. It is a neutral transaction.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders when they make transactions involving their company's stock. It is a routine disclosure and does not indicate any specific trend in the biotech industry.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transfer of shares to a family trust is a common estate planning strategy for executives and is not unusual in the biotech industry.
• The number of shares transferred is not significant enough to be considered unusual for a CEO of a company of this size.

Related Party Transactions

• The transfer of shares to a family trust is a related party transaction.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a transfer of shares and not a sale on the open market.
• The transfer does not impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Verve Therapeutics, Sekar Kathiresan, stock transfer, family trust, insider transaction, share ownership